Filing Flows › Vir Biotechnology (VIR) › Guidance & outlook

Vir Biotechnology (VIR) guidance and outlook

Vir Biotechnology's 10-Q filed Nov 4, 2026 makes 17 forward-looking statements.

Guidance and outlook

Forward-looking statements, 10-Q filed Nov 4, 2026

• Our clinical-stage portfolio includes programs for chronic hepatitis delta (CHD) and multiple PRO-XTEN ® dual-masked T-cell engagers (TCEs) across validated targets in solid tumor indications.
• • We will present expanded Phase 2 SOLSTICE results in oral presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting ® 2026 on November 8.
• We expect multiple pivotal trials to begin in 2027.
• Following recent feedback from the FDA, we intend to add backfill cohorts in a more homogeneous patient population in the monotherapy arm of the study to determine optimal dose and schedule.
• • We expect to present data at a future scientific conference.
• We do not expect to generate any significant revenue from the sale of our product candidates until we complete clinical development, submit regulatory filings and receive approvals from the applicable regulatory bodies for such product candidates, if ever.
• We expect our research and development expenses to increase substantially in absolute dollars over time as we advance our product candidates into and through preclinical and clinical studies and pursue regulatory approval of our product candidates.
• As a result of the uncertainties discussed above, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate significant revenue from the commercialization and sale of any of our product candidates.
• We anticipate that we will make determinations as to which product candidates to pursue and how much funding to direct to each product candidate on an ongoing basis in response to the results of ongoing and future preclinical and clinical studies, regulatory developments, our ongoing assessments as to each product candidate’s commercial potential.
• We cannot forecast which product candidates may be subject to future collaborations, when such arrangements will be secured (if at all) and to what degree such arrangements will affect our development plans and capital requirements.
• In the long-term as we advance our research and development programs toward potential commercialization, we expect our selling, general, and administrative expenses to increase in absolute dollars to support commercialization activities and related expansion in research and development activities.
• We will pay TD Cowen a commission of up to 3.0% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide TD Cowen with customary indemnification and contribution rights.

Vir Biotechnology's latest quarter

Questions

What does Vir Biotechnology expect?

Our clinical-stage portfolio includes programs for chronic hepatitis delta (CHD) and multiple PRO-XTEN ® dual-masked T-cell engagers (TCEs) across validated targets in solid tumor indications. • We will present expanded Phase 2 SOLSTICE results in oral presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting ® 2026 on November 8. We expect multiple pivotal trials to begin in 2027.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.